Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,441,777
  • Shares Outstanding, K 165,720
  • Annual Sales, $ 2,462 M
  • Annual Income, $ 274,920 K
  • 60-Month Beta 0.48
  • Price/Sales 3.68
  • Price/Cash Flow 19.05
  • Price/Book 4.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.58
  • Growth Rate Est. (year over year) +172,141.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.56 +4.50%
on 05/19/20
53.64 -5.39%
on 05/08/20
-1.88 (-3.57%)
since 04/27/20
3-Month
33.33 +52.27%
on 03/18/20
53.64 -5.39%
on 05/08/20
+8.66 (+20.57%)
since 02/27/20
52-Week
33.33 +52.27%
on 03/18/20
53.64 -5.39%
on 05/08/20
+12.59 (+32.99%)
since 05/24/19

Most Recent Stories

More News
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

RDY : 50.75 (-0.37%)
VRTX : 278.51 (+4.51%)
ABBV : 89.98 (-0.80%)
Dr. Reddy's Q4 & FY20 Financial Results

Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2020 under International Financial...

RDY : 50.75 (-0.37%)
Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the fourth quarter and full year ended March 31, 2020 on Wednesday, May 20, 2020 after the Board Meeting.

RDY : 50.75 (-0.37%)
Dr. Reddy's Laboratories Received Approval for Their NDA, ELYXYB(TM) (celecoxib oral solution) 25 mg/mL, in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced approval of ELYXYB (celecoxib oral solution 25 mg/mL)...

RDY : 50.75 (-0.37%)
Dr. Reddy's Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Desmopressin Acetate Injection USP,...

RDY : 50.75 (-0.37%)
Are You Looking for a Top Momentum Pick? Why Doctor Reddy's (RDY) is a Great Choice

Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.

RDY : 50.75 (-0.37%)
Dr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fenofibrate Tablets USP, a therapeutic...

RDY : 50.75 (-0.37%)
Zacks.com featured highlights include: Rocky Brands, FTI Consulting, Stamps.com, Sprouts Farmers Market and Dr. Reddy???s Laboratories

Zacks.com featured highlights include: Rocky Brands, FTI Consulting, Stamps.com, Sprouts Farmers Market and Dr. Reddy???s Laboratories

RDY : 50.75 (-0.37%)
RCKY : 21.92 (+7.82%)
SFM : 24.82 (+1.55%)
STMP : 185.76 (-0.08%)
Beat Coronavirus Blues With These 5 Low-Beta Stocks

A portfolio of low-beta stocks can protect your investments from the coronavirus-induced market volatility.

RDY : 50.75 (-0.37%)
FCN : 121.12 (+1.14%)
RCKY : 21.92 (+7.82%)
SFM : 24.82 (+1.55%)
STMP : 185.76 (-0.08%)
Dr. Reddy's Laboratories Announces the Launch of an Authorized Generic Version of NitroDur(R) (nitroglycerin) Transdermal Infusion System in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of authorized generic version of NitroDur(R)...

RDY : 50.75 (-0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RDY with:

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

2nd Resistance Point 52.36
1st Resistance Point 51.56
Last Price 50.75
1st Support Level 50.02
2nd Support Level 49.28

See More

52-Week High 53.64
Last Price 50.75
Fibonacci 61.8% 45.88
Fibonacci 50% 43.49
Fibonacci 38.2% 41.09
52-Week Low 33.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar